Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
COR.MX
BUYGet insider-trade alertsCencora, Inc. · Healthcare · United States · $50.4B · Avg Vol: $0/d
COMPANY DESCRIPTION
Cencora, Inc. is a global pharmaceutical sourcing and distribution giant, playing a critical role in the healthcare supply chain. The company benefits from an oligopolistic market structure in the United States, where it commands a massive market share alongside two other major distributors. Its competitive moat is defined by high barriers to entry, extensive logistics infrastructure, and long-term contracts with major healthcare providers and pharmacies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238.6B | 262.2B | 294.0B | 321.3B | 10.4% | 328.7B | 337.3B | 358.9B | 5.7% |
| EPS | 8.15 | 8.62 | 7.60 | 8.02 | -0.5% | 13.06 | — | — | — |
| Shares | 292.7M | 294.8M | 296.2M | 297.4M | +1.6% | — | — | — | — |
| Debt | 5.7B | 4.8B | 4.4B | 7.7B | 10.3% | 15.1B | — | — | — |
| Equity | -211.6M | 522.0M | 645.9M | 1.5B | 70.0% | — | — | — | — |
| Op CF | 2.7B | 3.9B | 3.5B | 3.9B | 12.8% | 2.3B | — | — | — |
| Inv CF | -368.4M | -2.6B | -618.1M | -5.0B | — | — | — | — | — |
| Fin CF | -1.8B | -2.2B | -2.3B | 2.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COR.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| COR.MX | Cencora, Inc.(you) | $50.4B | 75 | BUY |
| CAH | Cardinal Health, Inc. | $55.7B | 90 | STRONG BUY |
| MCK | McKesson Corporation | $89.4B | 84 | STRONG BUY |
| HSIC | Henry Schein, Inc. | $9.7B | 79 | BUY |
| 600332.SS | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $4.7B | 75 | BUY |
| 601607.SS | Shanghai Pharmaceuticals Holding Co., Ltd | $8.4B | 91 | STRONG BUY |
| SIG.AX | Sigma Healthcare Limited | $22.1B | 35 | HOLD |
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd | $3.4B | 80 | BUY |
| GALE.SW | Galenica AG | $5.3B | 61 | HOLD |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 96 | STRONG BUY |
Peer medians: ROE 2.8% · P/E 22.2x · Gross margin 47.0%